Most cancer drugs introduced since 2004 provide low added value compared to previously approved medications, but have much higher prices, according to a French study presented at the congress of the European Society for Medical Oncology [more]
Randomized controlled trials that have been used for the FDA approval of new anticancer drugs were sometimes based on a flawed design, with suboptimal control arms: “Using a suboptimal control arm may bias a trial in [more]
The US Food and Drug Administration issued a safety communication about robotically-assisted surgical procedures for cancer prevention or treatment, pointing out that their safety and effectiveness has not been established yet. In the Unites States, the [more]
Pembrolizumab is the first drug approved by the U.S. Food and Drug Administration for use based on a biomarker (a specific genetic feature) rather than the location in the body where the tumor originated. The drug is indicated [more]
When new cancer therapies regularly become available more than half a year earlier in the US than in Europe, or get regulatory approval on one side of the Atlantic but not on the other, patients [more]
Late last year, US patients with advanced renal cell cancer gained access to an oral multi-kinase inhibitor, Nexavar (sorafinib) the first new drug approved for this disease in the last 10 years. Manufacturer Bayer [more]